source
- Merck wins FDA nod for first oral PCSK9 inhibitor, Lipfendra, to treat high LDL cholesterolMerck announced that the U.S. Food and Drug Administration has approved its once-daily oral PCSK9 inhibitor, enlicitide, marketed as Lipfendra, for adults with elevated LDL cholesterol. The drug i…
- FDA approves Merck’s first oral PCSK9 inhibitor, marking a first for the drug classThe U.S. Food and Drug Administration has granted approval to Merck for its oral PCSK9 inhibitor, the first drug of this type to receive such clearance. The approval represents a milestone because…